Major depressive disorder (MDD) is a common psychiatric disorder, which is emerging mental disorder in most of the population. Imbalance in serotonin and norepinephrine neurotransmitters is thought to be the major cause of depressive disorder. Pharmacological management of MDD include first generation anti depressants such as Tri Cyclic Antidepressants (TCAs), Mono Amine Oxidase Inhibitors (MAOIs), and second generation antidepressants include Selective Serotonin Reuptake inhibitors (SSRIs) and Selective Norepinephrine Reuptake inhibitors (SNRIs). In the year 2013 Food and Drug Administration (FDA) approved two drugs for the treatment of MDD, namely levomilnacipran and vortioxetine.
Loading....